The discovery of the new properties of SSRs and DRs has led to a renewed interest in agents targeting these receptors and has opened new perspectives for medical treatment of patients with pituitary and neuroendocrine tumors resistant to the “classical”, currently available analogs. Moreover, SSRs and DRs crosstalk at membrane level may trigger alternative intracellular pathways or enhance the signalling for the control of cell growth. New somatostatin analogs and hybrid molecules, which display a broader and different spectrum of activities compared to conventional analogs, seem to be a promising therapeutic alternative for the control of hormone secretion and, hopefully, to reduce tumor burden. Receptor profile characterization is crucial for the accurate selection of patients potentially responsive to a given therapy. Free full text available at www.tumorionline.it
Get full access to this article
View all access options for this article.
References
1.
FeroneD., GattoF., ArvigoM., ResminiE., BoschettiM., TetiC., EspositoD., MinutoF.: The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol, 42: 361–370, 2009.
2.
FeroneD., de HerderW.W., PivonelloR., KrosJ.M., van KoetsveldP.M., de JongY., MinutoF., ColaoA., LambertsS.W.J., HoflandL.J.: Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron miroscopy. J Clin Endocrinol Metab, 93: 1412–1417, 2008.
3.
PivonelloR., FeroneD., de HerderW.W., KrosJ.M., Del Basso De CaroM.L., ArvigoM., AnnunziatoL., LombardiG., ColaoA., HoflandL.J., LambertsS.W.J.: Dopamine receptors expression and function in corticotroph pituitaty tumors. J Clin Endrocrinol Metab, 89: 2452–2462, 2004.
4.
PivonelloR., FeroneD., LambertsS.W.J., ColaoA.: Cabergoline plus lanreotide for ectopic Cushing's Sindrome. N Engl J Med, 352: 2457–2458, 2005.
5.
O'TooleD., SaveanuA., CouvelardA., GunzG., EnjalbertA., JaquetP., RuszniewskiP., BarlierA.: The analysis if quantitative expression of somatostatin and dopamine receptors in gastroenteropancreatic tumors opens new therapeutic strategies. Eur J Endocrinol, 155: 849–857, 2006.
6.
SrirajaskanthanR., WatkinsJ., MarelliL., KhanK., CaplinM.E.: Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumors and the potential role for new bio-therapies. Neuroendocrinol, 89: 308–314, 2009.
7.
SaveanuA., GunzG., DufourH., CaronP., FinaF., OuafikL., CullerM.D., MoreauJ.P., EnjalbertA., JaquetP.: BIM-23244, a somatostatin receptor subtype 2– and 5– selective analog with enhanced efficacy in suppressing growth hormone (GH) from otcreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab, 86: 140–145, 2001.
8.
HoflandL.J., van der HoekJ., van KoetsveldP.M., de HerderW.W., WaaijersM., Sprij-MooijD., BrunsC., WeckbeckerG., FeeldersR., van der LelyA-J, BeckersA., LambertsS.W.J.: The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas in Vitro. J Clin Endrocrinol Metab, 89: 1577–1585, 2004.
9.
JaquetP., GunzG., SaveanuA., DufourH., TaylorJ., DongJ., KimS., MoreauJ-P, EnjalbertA., CullerM.D.: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol, 153: 135–141, 2005.
10.
FlorioT., BarbieriF., SpazianteR., ZonaG., HoflandL.J., van KoetsveldP.M., FeeldersR.A., StallaG.K., TheodoropoulouM., CullerM.D., DongJ., TaylorJ.E., MoreauJ-P, SaveanuA., GunzG., DufourH., JaquetP.: Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endrocr Relat Cancer, 15: 583–596, 2008.
11.
FeroneD., ArvigoM., SeminoC., JaquetP., SaveanuA., TaylorJ.E., MoreauJ-P, CullerM.D., AlbertelliM., MinutoF., BarrecaA.: Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am JPhysiol Endocrinol Metab, 289: E1044–1050, 2005.
12.
KiddM., DrozdovI., JosephR., PfragnerR., CullenM., ModlinI.: Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer, 113: 690–700, 2008.
13.
RochevilleM., LangeD.C., KumarU., PatelS.C., PatelR.C., & PatelY.C.: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 288: 154–157, 2000.
14.
AngersS., SalahpourA., BouvierM.: Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annual Review of Pharmacology and Toxicology, 42: 409–435, 2002.
15.
PfeifferM., KochT., SchroderH., KlutznyM., KirschtS., KreienkampH.J., HolltV., and SchulzS.: Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem276: 14027–14036, 2001.
